Phase I and pharmacokinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies.

被引：0
|
作者：
Attard, G
Plummer, RE
De Bono, JS
Bale, C
Fong, P
Barrett, M
Fox, NL
Howard, T
Ullrich, S
Calvert, H
机构：
[1] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[2] No Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England
[3] Human Genome Sci, Rockville, MD USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9060S / 9060S
页数：1
相关论文
共 50 条
  • [21] A phase I first-in-human study of REGN910 (SAR307746), a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb), in patients with advanced solid tumor malignancies.
    Papadopoulos, Kyriakos P.
    Sahebjam, Solmaz
    Kelley, Robin Katie
    Tolcher, Anthony W.
    Razak, Albiruni R. A.
    Patnaik, Amita
    Bedard, Philippe L.
    Arcos, Rebecca
    Adriaens, Lieve
    Brownstein, Carrie M.
    Lowy, Israel
    Gao, Bo
    DiCioccio, A. Thomas
    Trail, Pamela
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies.
    Dupont, J
    Schwartz, L
    Koutcher, J
    Spriggs, D
    Gordon, M
    Mendelson, D
    Murren, J
    Lucarelli, A
    Cedarbaum, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 197S - 197S
  • [23] HGS-E-.-R2, a fully human agonist monoclonal antibody that targets TRAIL-R2, synergizes with chemotherapeutic agents to increase in vitro cytotoxicity and induce tumor regression in NSCLC xenografts.
    Humphreys, RC
    Shepard, L
    Poortman, C
    Carrell, J
    Albert, V
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9039S - 9039S
  • [24] Results of a phase 2 trial of HGS-ETR1 (Agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL).
    Younes, A
    Vose, JM
    Zelenetz, AD
    Smith, MR
    Burris, H
    Ansell, S
    Klein, J
    Kumm, E
    Czuczman, M
    BLOOD, 2005, 106 (11) : 146A - 147A
  • [25] Phase I expansion study of sunitinib and bevacizumab in patients with advanced solid malignancies.
    Mittal, Kriti
    Koon, Henry B.
    Elson, Paul
    Triozzi, Pierre L.
    Dowlati, Afshin
    Borden, Ernest C.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/recurrent non-small cell lung cancer (NSCLC)
    Bonomi, P
    Greco, F
    Crawford, J
    Kelly, K
    Oh, Y
    Klein, J
    LUNG CANCER, 2005, 49 : S238 - S238
  • [27] Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
    Lee, Su Jin
    Lee, Seon Young
    Lee, Weon Sup
    Yoo, Jin San
    Sun, Jong-Mu
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Ahn, Myung-Ju
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Young Suk
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 782 - 790
  • [28] Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
    Su Jin Lee
    Seon Young Lee
    Weon Sup Lee
    Jin San Yoo
    Jong-Mu Sun
    Jeeyun Lee
    Se Hoon Park
    Joon Oh Park
    Myung-Ju Ahn
    Ho Yeong Lim
    Won Ki Kang
    Young Suk Park
    Investigational New Drugs, 2017, 35 : 782 - 790
  • [29] A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
    Camidge, D. Ross
    Herbst, Roy S.
    Gordon, Michael S.
    Eckhardt, S. Gail
    Kurzrock, Razelle
    Durbin, Blythe
    Ing, Josephine
    Tohnya, Tanyifor M.
    Sager, Jason
    Ashkenazi, Avi
    Bray, Gordon
    Mendelson, David
    CLINICAL CANCER RESEARCH, 2010, 16 (04) : 1256 - 1263
  • [30] Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies
    Argiris, Athanassios
    Feinstein, Trevor M.
    Wang, Lin
    Yang, Tianbing
    Agrawal, Shruti
    Appleman, Leonard J.
    Stoller, Ronald G.
    Grandis, Jennifer R.
    Egloff, Ann Marie
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1575 - 1584
12345